Founded in 2006, EOS is headquartered in Milan, Italy and is committed to the development of novel medicines for cancer treatment. The company is seeking to build a portfolio of molecular targeted anticancer agents, with a preference for small molecules. EOS aims to form partnerships with early stage companies to develop these agents until proof of concept in patients. Additionally, EOS provides anti-proliferative agents and multikinase inhibitors.